{"organizations": [], "uuid": "c21d7dad8c471a10cc32ee91e026e41ce49b25c0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-therapix-biosciences-expects-to-te/brief-therapix-biosciences-expects-to-test-thx-110-in-early-study-in-q2-idUSFWN1PX1A1", "country": "US", "domain_rank": 408, "title": "BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.596, "site_type": "news", "published": "2018-02-07T21:36:00.000+02:00", "replies_count": 0, "uuid": "c21d7dad8c471a10cc32ee91e026e41ce49b25c0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-therapix-biosciences-expects-to-te/brief-therapix-biosciences-expects-to-test-thx-110-in-early-study-in-q2-idUSFWN1PX1A1", "ord_in_thread": 0, "title": "BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "therapix biosciences ltd", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "tourette", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 7, 2018 / 1:36 PM / in 14 minutes BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2 Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Therapix Biosciences Ltd: \n* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018 \n* THERAPIX BIOSCIENCES - COMPLETES PRE-IND COMMUNICATION WITH FDA ON THX-110 FOR TOURETTE SYNDROME: CLINICAL DEVELOPMENT TO PROCEED AS PROJECTED Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T21:36:00.000+02:00", "crawled": "2018-02-07T15:54:37.010+02:00", "highlightTitle": ""}